ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Signal Transduct Target Ther · 2025 · PMC11830773 · PMID 39956849

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

A favorable trend in OS was indicated and consistent results were observed across all key subgroups (Figs. 4 , 5 ).

also in 805 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.